Evidence map›Paper›PMID 39405600›Full record

ArticleDrug and alcohol dependence2024

Time course of kratom effects via ecological momentary assessment, by product type, dose amount, and assayed alkaloid content.

Kirsten E Smith, Leigh V Panlilio, Abhisheak Sharma, Christopher R McCurdy, Jeffrey D Feldman, Sushobhan Mukhopadhyay, Siva Rama Raju Kanumuri, Michelle A Kuntz, Katherine Hill, David H Epstein

Abstract read
In one paragraph

Article in Drug and alcohol dependence, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Kirsten E SmithDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, United States. Electronic address: ksmit398@jh.edu.
Leigh V PanlilioReal-World Assessment, Prediction, and Treatment Unit, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD, United States.
Abhisheak SharmaDepartment of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, FL, United States.
Christopher R McCurdyDepartment of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL, United States.
Jeffrey D FeldmanDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Sushobhan MukhopadhyayDepartment of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL, United States.
Siva Rama Raju KanumuriDepartment of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, FL, United States.
Michelle A KuntzDepartment of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, FL, United States.
Katherine HillDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, United States.
David H EpsteinDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, United States.

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Kratom alkaloids: in vitro and in vivo pharmacological mechanismsR01DA047855 · NIDA · UNIVERSITY OF FLORIDA · PI MCCURDY, CHRISTOPHER R, MCMAHON, LANCE R. · 2019 to 2023
$3.6M
NCATS NIH HHS UL1 TR001863NIDA NIH HHS K99 DA055571NIDA NIH HHS R01 DA047855
6 · The paper itself

Abstract

BACKGROUND AND

aimsUsing ecological momentary assessment (EMA), we undertook a natural experiment wherein kratom-product variability was a tool to assess kratom dose-response relationships based on product form and alkaloid level.

methodsBetween July-November 2022, 357 US kratom consumers (56.6 % male, 90.2 % non-Hispanic white) completed 15 days of EMA; 348 participants submitted samples of the products used most often during EMA. These were assayed for ten alkaloids using ultra-performance liquid chromatography-tandem mass spectrometry. Self-reported kratom effects were modeled as a function of kratom amount and alkaloid content.

resultsParticipants used over 220 brands. The most-reported product forms were loose powder (55.8 %) and encapsulated powder (26.8 %); extracts were used less (419 uses across 9.48 % of participants). Of the 12,244 use-event entries, 7726 had follow-up data (15-180minutes after use) on felt effects. Effects were stronger in participants with a higher average amount per use. Within-person dose-response relationships were obscured by highly-consistent within-person dosages. Effects of loose powder decreased over three hours; effects of extracts started higher but decreased more rapidly. Dose-response relationships for specific alkaloids could not be reliably established because total alkaloid content and relative levels of specific alkaloids showed limited variability between products. Higher levels of corynoxine alkaloids were associated with slightly stronger effects, possibly an artifact of modeling data with low alkaloid variability.

conclusionsAlkaloid content was surprisingly consistent across kratom products, and participants were consistent in the amount they used across events. Firm conclusions about alkaloid-effect relationships for kratom will require experimenter-controlled manipulations of agent and dose.

Indexed as

AlkaloidsMitragynaAdolescentAdultDose-Response Relationship, DrugEcological Momentary AssessmentFemaleHumansMaleMiddle AgedPlant ExtractsYoung AdultAlkaloidsPlant ExtractsEcological momentary assessmentExtractsKratomMitragyna speciosaMitragynine

Identifiers

PMID39405600
PMCPMC11527584

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.